COX-2, cell proliferation and PMA in head-and-neck cancer cells

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 203-218

  Cao, H James ^a   Lin, Hung Yun ^a   Luidens, Mary K ^a,b   Keating, Travis ^a   Grandis, Jennifer R ^c   Davis, Faith B ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenases; Head and neck cancer cells; P21; P53; Phorbol ester; Protein kinase C

Indexed keywords

CYCLOOXYGENASE 2; NUCLEOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E2; PROTEIN P21; PROTEIN P300; PROTEIN P53; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PROMOTER REGION; T LYMPHOCYTE;

EID: 77249110315     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152209790773002     Document Type: Article

References (65)

1. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature, 1984, 308, 693-698.
2. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature, 1988, 334, 661-665.
3. Parker, P.J.; Murray-Rust, J. PKC at a glance. J. Cell Sci., 2004, 117, 131-132.
4. Smith, W.L.; Garavito, R.M.; DeWitt, D.I. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem., 1996, 271, 33157-33160.
5. Smith, W.L.; DeWitt, D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol., 1996, 62, 167-215.
6. Wang, Q.; Xu, J.; Rottinghause, G.E.; Simonyi, A.; Lubahn, D; Sun, G.Y.; Sun, A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958, 439-447.
7. Fink, C.D., Funk, L.B., Kennedy, M.E.; Peng, A.S.; Fitzgerald, G.A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J., 1991, 5, 2304-2312.
8. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem., 2000, 69, 145-182.
9. Cao, H.J.; Han, R.; Smith, T.J. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am. J. Physiol Cell Physiol., 2003, 284, C1429-C1437.
10. Cao, H.J.; Smith, T.J. Leukoregulin upregulation of prostaglanding endoperoxide H synthase-2 expression in human orbital fibroblasts. Am. J. Physiol., 1999, 277, C1075-C1085.
11. Cao, H.J.; Wang, H.S.; Zhang, Y.; Lin, H.Y.; Phipps, R.P.; Smith, T.J. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-assoicated opthalmopathy. J. Biol. Chem., 1998, 273, 29615-29625.
12. Davies, G., Martin, L.A.; Sacks, N.; Dowsett, M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol., 2002, 13, 669-678.
13. Gately, S. The contributions of cycolooxygeanse-2 to tumor angiogenesis. Cancer Metastasis Rev., 2000, 19, 19-27.
14. Lion, J.Y., Deng, W.G., Guilroy, D.W.; Shyue, S.K.; Wu, K.K. Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J. Biol. Chem., 2001, 276, 34975-34982.
15. Tsutsumi, S.; Mima, S.; Tomisato, W.; Hoshino, T.; Tsuchiya, T.; Mizushima, T. Molecular mechanism of adaptive cytoprotection induced by ethanol in human gastric cells. Exp. Biol. Med. (Maywood), 2003, 228, 1089-1095.
16. Ishaque, A.; Dunn, M.J.; Sorokin, A. Cyclooxygenase-2 inhibits tumor necrosis factor-α-mediated apoptosis in renal glomerular mesangial cells. J. Biol. Chem., 2003, 278, 10629-10640.
17. Lim, J.W.; Kim, H.; Kim, K.H. Expression of Ku70 and Ku80 mediated by NF-κB and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J. Biol. Chem., 2002, 277, 46093-46100.
18. Gasparini, G.; Longo, R.; Torino, F.; Morabito, A. Therapy of breast cancer with molecular targeting agents. Ann. Oncol., 2005, 16(Suppl 4), iv28-iv36.
19. Zheng, W.; Weiss, R.M.; Wang, X.; Zhou, R.; Arlen, A.M.; Lei, L.; Lazartigues, E.; Tomanek, R.J. DITPA stimulates arteriolar growth and modifies myocardial post-infarction remodeling. Am. J. Physiol. Heart Circ. Physiol., 2004, 286, H1994-H2000.
20. Patel, V.A.; Dunn, M.J.; Sorokin, A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem., 2002, 277, 38915-38920.
21. Han, J.A.; Kim, J.I.; Ongusaha, P.P.; Hwang, D.H.; Ballou, L.R.; Mahale, A. p53-mediated induction of COX-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J., 2002, 21, 5635-5644.
22. Subbaramaiah, K.; Altorki, N.; Chung, W.J.; Mestre, J.R.; Sampat, A.; Dannenberg, A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 1999, 274, 10911-10915.
23. Liu, X.H.; Kirschenbaum, A.; Yu, K.; Yao, S.; Levine, A.C. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J. Biol. Chem., 2005, 280, 3817-3823.
24. Morita, I.; Schindler, M.; Regier, M.K.; Otto, J.C.; Hori, T.; DeWitt, D.L.; Smith, W.L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem., 1995, 270, 10902-10908.
25. Moll, U.M.; Ostermeyer, A.G.; Haladaym R.; Winkfield, B.; Frazier, M.; Zambetti, G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol., 1996, 16, 1126-1137.
26. Kovacs, A.; Weber, M.L.; Burns, L.J.; Jacob, H.S.; Vercellotti, G.M. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am. J. Pathol., 1996, 149, 1531-1539.
27. Lin, H.Y.; Shih, A.; Davis, F.B.; Davis, P.J. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem. J., 1999, 338(Pt. 2), 427-432.
28. Meade, E.A.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem., 1999, 274, 8328-8334.
29. Luo, J.; Lang, J.A.; Miller, M.W. Transforming growth factor-β1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. J. Neurochem., 1998, 71, 526-534.
30. Sperling, R.; Braunstein, M.; Melin, J.; Reicin, A. Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al. Arthritis Rheum., 2001, 44, 1229-1230.
31. Feng, X.; Hannum, Y.A. An essential role for autophosphorylation in the dissociation of activated protein kinase C from the plasma membrane. J. Biol. Chem., 1998, 273, 26870-26874.
32. Smith, W.L.; Rollins, T.E.; DeWitt, D.L. Subcellular localization of prostaglandin forming enzymes using conventional and monoclonal antibodies. Prog. Lipid Res., 1981, 20, 103-110.
33. Pang, L.; Nie, M.; Corbett, L.; Donnelly, R.; Gray, S.; Knox, A.J. Protein kinase C-epsilon mediates bradykinin-induced cyclooxygenase-2 expression in human airway smooth airway cells. FASEB J., 2002, 16, 1435-1437.
34. Goppelt-Struebe, M.; RFehm, M.; Schaefers, H.J. Induction of cyclooxygenase-2 by platelet-derived growth factor (PDGF) and its inhibition by dexamethasone are independent if NF-κB/IκB transcription factors. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 361, 636-645.
35. Wang, Z.; Tai, H.H. Interleukin-1β and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NF-κB pathway in human amnion derived WISH cells. Prostaglandins Leukot. Essent. Fatty Acids, 1998, 59, 63-69.
36. Shinmura, K.K.; Tang, X.L.; Wang, Y.; Xuan, Y.T.; Liu, S.Q.; Takano, H.; Bhatnagar, A.; Bolli, R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. USA, 2000, 97, 10197-10202.
37. Steinauer, K.K.; Gibbs, I.; Ning, S.; French, J.N.; Armstrong, J.; Knox, S.J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int. J. Radiat. Oncol. Biol. Phys., 2000, 48, 325-328.
38. Couldwell, W.T.; Antel, J.P.; Yong, V.W. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulation of protein kinase C. Neurosurgery, 1992, 31, 717-724; discussion, 724.
39. Fishmanm D.D.; Segal, S.; Livneh, E. The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int. J. Oncol., 1998, 12, 181-186.
40. Livneh, E., Fishman, D.D. Linking protein kinase C to cell-cycle control. Eur. J. Biochem., 1997, 248, 1-9.
41. Hamada, K.; Takuwa, N.; Zhou, W.; Kumada, M.; Takuwa, Y. Protein kinase C inhibits the CAK-CDK2 cyclin-dependent kinase cascade and G1/S cell cycle progression in human diploid fibroblasts. Biochim. Biophys. Acta, 1996, 1310, 149-156.
42. Frey, M.R.; Saxon, M.L.; Zhao, X.; Rollins, A.; Evans, S.S.; Black, J.D. Protein kinase C isoenzyme-mediated cell cycle stress involves induction of p21(waf1/cip1) and p21(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J. Biol. Chem., 1997, 272, 9424-9435.
43. Delphin, C.; Ronjat, M.; Deloulme, J.C.; Garin, G.; Debussche, L.; Higashimoto, Y.; Sakaguchi, K.; Baudier, J. Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53. J. Biol. Chem., 1999, 274, 10539-10544.
44. Akashi, M.; Osawa, Y.; Koeffler, H.P.; Hachiya, M. p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem. J., 1999, 337(Pt. 3), 607-616.
45. Shaw, G.; Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell, 1986, 46, 659-667.
46. Yang, W.; El-Deiry, W.S. CARPs are E3 ligases that target apical caspases and p53. Cancer Biol. Ther., 2007, 6, 1676-1683.
47. Hla, T.; Neilson, K. Human cyclooxygenase-2 DNA. Proc. Natl. Acad. Sci. USA, 1992, 89, 7384-7388.
48. Lindstein, T.; June, C.H.; Ledbetter, J.A.; Stella, G.; Thompson, C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Scienc, 1989, 244, 339-343.
49. Choi, E.M.; Heo, J.I.; Oh, J.Y.; Kim, Y.M.; Ha, K.S.; Kim, J.I.; Han, J.A. COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem. Biophys. Res. Commun., 2005, 328, 1107-1112.
50. Corcoran, C.A.; He, Q.; Huan, Y.; Sheikh, M.S. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene, 2005, 24, 1634-1640.
51. Zimmermann, K.C.; Sarbia, M.; Weber, A.A.; Borchard, F.; Gabbert, H.E.; Schror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 1999, 59, 198-204.
52. Yu, H.P.; Xu, S.Q.; Liu, L.; Shi, L.Y.; Cai, X.K.; Lu, W.H.; Lu, B.; Su, Y.H.; Li, Y.Y. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell cafrcinoma of the esophagus. Cancer Lett., 2003, 198, 193-201.
53. Yoshimura, R.; Sano, H.; Masuda, C.; Kawamura, M.; Tsubouchi, Y.; Chargui, J.; Yoshimura, N.; Hla, T.; Wada, S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer, 2000, 89, 589-596.
54. Buchanan, F.G.; DuBois, R.N. Connecting COX-2 and Wnt in cancer. Cancer Cell, 2006, 9, 6-8.
55. Kumar, R. Commentary: targeting colorectal cancer trough molecular biology. Semin. Oncol., 2005, 32, 37-39.
56. Hendrickx, N.; Volanti, C.; Moens, U.; Seternes, O.M.; de Witte, P.; Vandenheede, J. R.; Piette, J.; Agostinis, P. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J. Biol. Chem., 2003, 278, 52231-52239.
57. Pai, R.; Soreghan, B.; Szabo, I.L.; Pavelka, M.; Baatar, D.; Tarnawski, A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 2002, 8, 289-293.
58. Howe, L.R.; Subbaramaiah, K.; Brown, A.M.; Dannenberg, A.J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer, 2001, 8, 97-114.
59. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
60. Parfenova, H.; Parfenov, V.N.; Shlopov, B.V.; Levine, B.; Falkos, F.; Pourcyrous, M.; Leffler, C.W. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am. J. Physiol. Cell Physiol., 2001, 281, C166-C178.
61. Marvin, K.W.; Eykholt, R.L.; Mitchell, M.D. Subcellular localization of prostaglandin H synthase-2 in a human amnion cell line: implications for nuclear localized prostaglandin signaling pathways. Prostaglandins Leukot. Essent. Fatty Acids, 2000, 62, 7-11.
62. Hwang, D.; Fischer, N.H.; Jang, B.C.; Tak, H.; Kim, J.K.; Lee, W. Inhibition of the expression of inducible cyclooxygenases and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with inhibition of MAP kinases. Biochem. Biophys. Res. Commun., 1996, 226, 810-818.
63. Guo, Y.S.; Hellmich, M.R.; Wen, X.D.; Townsend, C.M., Jr. Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J. Biol. Chem., 2001, 276, 22941-22947.
64. Subbaramaiah, K.; Norton, L.; Gerald, W.; Dannenberg, A.J. Cyclooxygenase-2 is overexpressed in HER-2 neupositive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem., 2002, 277, 18649-18657.
65. Deng, W.G.; Zhu, Y.; Wu, K.K. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood, 2004, 103, 2135-2142.